Tumor Necrosis Factor-α +489G/A gene polymorphism is associated with chronic obstructive pulmonary disease

Respiratory Research

Emiel FM Wouters¹  Mieke A Dentener¹  Wim A Buurman²  Tom WJ Huizinga³  Herman-Jan Pennings⁴  Michiel Van Krugten³  Mehmet Küçükaycan¹ 

[1] Nutrition and Toxicology Research Institute Maastricht (NUTRIM), Department of Pulmonology, Maastricht University, Maastricht, The Netherlands;Nutrition and Toxicology Research Institute Maastricht (NUTRIM), Department of Surgery, Maastricht University, Maastricht, The Netherlands;Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands;Hornerheide, Pulmonary Rehabilitation Centre, Horn, The Netherlands

关键词: Tumor necrosis factor-α;    Susceptibility;    Gene polymorphism;    COPD;    Caucasians;   

Others  :  1227392
DOI  :  10.1186/rr194

 received in 2001-11-01, accepted in 2002-08-13,  发布年份 2002

【 摘 要 】

Background

Chronic obstructive pulmonary disease (COPD) is characterized by a chronic inflammatory process, in which the pro-inflammatory cytokine Tumor Necrosis Factor (TNF)-α is considered to play a role. In the present study the putative involvement of TNF-α gene polymorphisms in pathogenesis of COPD was studied by analysis of four TNF-α gene polymorphisms in a Caucasian COPD population.

Methods

TNF-α gene polymorphisms at positions -376G/A, -308G/A, -238G/A, and +489G/A were examined in 169 Dutch COPD patients, who had a mean forced expiratory volume in one second (FEV1) of 37 ± 13%, and compared with a Dutch population control group of 358 subjects.

Results

The data showed that the TNF-α +489G/A genotype frequency tended to be different in COPD patients as compared to population controls, which was due to an enhanced frequency of the GA genotype. In line herewith, carriership of the minor allele was associated with enhanced risk of development of COPD (odds ratio = 1.9, p = 0.009). The other TNF-α gene polymorphisms studied revealed no discrimination between patients and controls. No differences in the examined four TNF-α polymorphisms were found between subtypes of COPD, which were stratified for the presence of radiological emphysema. However, comparison of the COPD subtypes with controls showed a significant difference in the TNF-α +489G/A genotype in patients without radiological emphysema (χ²-test: p < 0.025 [Bonferroni adjusted]), while no differences between COPD patients with radiological emphysema and controls were observed.

Conclusion

Based on the reported data, it is concluded that COPD, and especially a subgroup of COPD patients without radiological emphysema, is associated with TNF-α +489G/A gene polymorphism.

【 授权许可】

   
2002 Küçükaycan et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any non-commercial purpose, provided this notice is preserved along with the article's original URL.

【 参考文献 】

• [1]Wilson AG, di Giovine FS, Blakemore AI, Duff GW: Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. Hum Mol Genet 1992, 1:353.
• [2]Hamann A, Mantzoros C, Vidal-Puig A, Flier JS: Genetic variability in the TNF-alpha promoter is not associated with type II diabetes mellitus (NIDDM). Biochem Biophys Res Commun 1995, 211:833-839.
• [3]D'Alfonso S, Richiardi PM: An intragenic polymorphism in the human tumor necrosis factor alpha (TNFA) chain-encoding gene. Immunogenetics 1996, 44:321-322.
• [4]Nuntayanuwat S, Dharakul T, Chaowagul W, Songsivilai S: Polymorphism in the promoter region of tumor necrosis factor-alpha gene is associated with severe meliodosis. Hum Immunol 1999, 60:979-983.
• [5]Cabrera M, Shaw MA, Sharples C, Williams H, Castes M, Convit J, Blackwell JM: Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis. J Exp Med 1995, 182:1259-1264.
• [6]McGuire W, Hill AV, Allsopp CE, Greenwood BM, Kwiatkowski D: Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria. Nature 1994, 371:508-510.
• [7]Westendorp RGJ, Langermans JAM, Huizinga TWJ, Verweij CL, Sturk A: Genetic influence on cytokine production in meningococcal disease. Lancet 1997, 349:1912-1913.
• [8]Brinkman BM, Huizinga TW, Breedveld FC, Verweij CL: Allele-specific quantification of TNFA transcripts in rheumatoid arthritis. Hum Genet 1996, 97:813-818.
• [9]Moffatt MF, Cookson WOCM: Tumour necrosis factor haplotypes and asthma. Hum Mol Gen 1997, 6:551-554.
• [10]Chagani T, Paré PD, Zhu S, Weir TD, Bai TR, Behbehani NA, Fitzgerald JM, Sandford AJ: Prevalence of tumor necrosis factor-α and angiotensin converting enzyme polymorphisms in mild/moderate and fatal/near fatal asthma. Am J Respir Crit Care Med 1999, 160:278-282.
• [11]Albuquerque RV, Hayden CM, Palmer LJ, Laing IA, Rye PJ, Gibson NA, Burton PR, Goldblat J, Lesouëf : Association of polymorphisms within the tumour necrosis factor (TNF) genes and childhood asthma. Clin Exp Allergy 1998, 28:578-584.
• [12]Louis R, Leyder E, Malaise M, Bartsch P, Louis E: Lack of association between adult asthma and the tumour necrosis factor α-308 polymorphism gene. Eur Respir J 2000, 16:604-608.
• [13]Huizinga TW, Westendorp RG, Bollen EL, Keijsers V, Brinkman BM, Langermans JA, Breedveld FC, Verweij CL, van de Gaer L, Dams L, Crusius JB, Garcia-Gonzalez A, van Oosten BW, Polman CH, Pena AS: TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol 1997, 72:149-153.
• [14]Grove J, Daly AK, Bassendine MF, Day CP: Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 1997, 26:143-146.
• [15]Beraun Y, Nieto A, Collado MD, Gonzalez A, Martin J: Polymorphisms at tumor necrosis factor (TNF) loci are not associated with Chagas' disease. Tissue Antigens 1998, 52:81-83.
• [16]Zhai R, Jetten M, Schins RP, Franssen H, Borm PJ: Polymorphisms in the promoter of the tumor necrosis factor-alpha gene in coal miners. Am J Ind Med 1998, 34:318-324.
• [17]Knight JC, Udalova I, Hill AV, Greenwood BM, Peshu N, Marsh K, Kwiatkowski D: A polymorphism that affects OCT-1 binding to the TNF promoter region is associated with severe malaria. Nature Genet 1999, 22:145-150.
• [18]Kaijzel EL, van Krugten MV, Brinkman BM, Huizinga TW, van der Straaten T, Hazes JM, Ziegler-Heitbrock HW, Nedospasov SA, Breedveld FC, Verweij CL: Functional analysis of a human tumor necrosis factor alpha (TNF-alpha) promoter polymorphism related to joint damage in rheumatoid arthritis. Mol Med 1998, 4:724-733.
• [19]Oh BR, Sasaki M, Perinchery G, Ryu SB, Park YI, Caroll P, Dahiya R: Frequent genotype changes at -308, and 488 regions of the tumor necrosis factor-α (TNF-α) gene in patients with prostate cancer. J. Urol 2000, 163:1584-1587.
• [20]Mullighan CG, Fanning GC, Chapel HM, Welsh KI: TNF and lymphotoxin-alpha polymorphisms associated with common variable immunodeficiency: role in the pathogenesis of granulomatous disease. J Immunol 1997, 159:6236-6241.
• [21]Van Krugten M, Huizinga T, Kaijzel E, Zanelli E, Drossaers-Bakker K, van de Linde P, Hazes J, Zwinderman A, Breedveld F, Verweij C: Association of the TNF +489 polymorphism with susceptibilty and radiographic damage in rheumatoid arthritis patients. Genes Immun 1999, 1:91-96.
• [22]Pantelidis P, Fanning F, Wels AU, Welsh KI, Du Bois RM: Analysis of tumor necrosis factor-α, lymphotoxin-α, tumor necrosis factor receptor II, and interleukin-6 polymorphisms in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001, 163:1432-1436.
• [23]Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW: Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A 1997, 94:3195-3199.
• [24]Kroeger K, Carville K, Abraham L: The -308 Tumor Necrosis Factor-a promotor polymorphism effects transcription. Mol Immunol 1997, 34:391-399.
• [25]Brinkman BM, Zuijdeest D, Kaijzel EL, Breedveld FC, Verweij CL: Relevance of the tumor necrosis factor alpha (TNF alpha) -308 promoter polymorphism in TNF alpha gene regulation. J Inflamm 1995, 46:32-41.
• [26]Uglialoro AM, Turbay D, Pesavento PA, Delgado JC, McKenzie FE, Gribben JG, Hartl D, Yunis EJ, Goldfeld AE: Identification of three new single nucleotide polymorphisms in the human tumor necrosis factor-α gene promoter. Tissue Antigens 1998, 52:359-367.
• [27]Keatings VM, Collins PD, Scott DM, Barnes PJ: Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996, 153:530-534.
• [28]Takabatake N, Nakamura H, Abe S, Inoue S, Hino T, Saito H, Yuki H, Kato S, Tomoike H: The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000, 161:1179-1184.
• [29]Huang SL, Su CH, Chang SC: Tumor necrosis factor-alpha gene polymorphism in chronic bronchitis. Am J Respir Crit Care Med 1997, 156:1436-1439.
• [30]Sakao S, Tatsumi K, Igari H, Shino Y, Shirasawa H, Kuriyama T: Association of tumor necrosis factorα gene promoter polymorphism with the presence of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 163:420-422.
• [31]Higham M, Pride N, Alikhan A, Morrell M: Tumor necrosis factor-a gene promoter polymorphism in chronic obstructive pulmonary disease. Eur Respir J 2000, 15:281-284.
• [32]Patuzzo C, Gile LS, Zorzetto M, Trabetti E, Malerba G, Pignatti PF, Luisetti M: Tumor necrosis factor gene complex in COPD and disseminated bronchiectasis. Chest 2000, 117:1353-1358.
• [33]Keatings VM, Cave SJ, Henry MJ, Morgan K, O'Connor CM, FitzGerald MX, Kalsheker N: A polymorphism in the tumor necrosis factor-alpha gene promoter region may predispose to a poor prognosis in COPD. Chest 2000, 118:971-975.
• [34]Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. American Thoracic Society. Am J Respir Crit Care Med 1995, 152:S77-S121.
• [35]Kaijzel E, Bayley J-P, Van Krugten M, Smith L, Van de Linde P, Bakker A, Breedveld F, Huizinga T, Verweij C: Allele-specific quantification of tumor necrosis factor (TNF) α transcription and the role of promoter polymorphisms in rheumatoid arthritis patients and healthy individuals. Genes Immun 2001, 2:135-144.
• [36]Sakai F, Gamsu G, Im JG, Ray CS: Pulmonary function abnormalities in patients with CT-determined emphysema. J Comput Assist Tomogr 1987, 11:963-968.
• [37]Lamers RJ, Thelissen GR, Kessels A, Wouters EFM, Van Engelshoven JM: Chronic obstructive pulmonary disease: evaluation with spirometrically controlled CT lung densitometry. Radiology 1994, 193:109-113.
• [38]Sterk PJ, Fabbri LM, Quanjer PH, Cockcroft DW, O'Byrne PM, Anderson SD, Juniper EF, Malo JL: Airway responsiveness. Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adults. Eur Respir J 1993, 16:53-83.
• [39]Gould GA, MacNee W, McLean A, Warren PM, Redpath A, Best JJ, Lamb D, Fenley DC: Measurements of lung density in life can quantitate distal airspace enlargement – an essential defining feature of human emphysema. Am Rev Respir Dis 1988, 37:380-392.
• [40]Aguado B, Milner CM, Campbell RD: Genes of the MHC class III region and the functions of the proteins they encode. In In HLA and MHC: Genes, Molecules and Function. Edited by Browning M, McMichael A. Oxford: BIOS Scientific Publishers; 1996:39-75.